Emergent Biosolutions EBS Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $156.1M+5.0% | $148.7M-35.7% | $231.1M+64.0% | $140.9M-36.6% | $222.2M+14.1% | ||
| $72M-15.2% | $84.9M-1.2% | $85.9M+28.4% | $66.9M-24.4% | $88.5M-25.0% | ||
| $84.1M+31.8% | $63.8M-56.1% | $145.2M+96.2% | $74M-44.7% | $133.7M+74.3% | ||
| 53.9%+11.0pp | 42.9%-19.9pp | 62.8%+10.3pp | 52.5%-7.7pp | 60.2%+20.8pp | ||
| $10.5M-13.2% | $12.1M-10.4% | $13.5M+8.0% | $12.5M-17.2% | $15.1M+65.9% | ||
| $46.6M-8.8% | $51.1M+31.4% | $38.9M-11.0% | $43.7M-16.6% | $52.4M-13.8% | ||
| $16.5M+1.2% | $16.3M0.0% | $16.3M+0.6% | $16.2M-0.6% | $16.3M0.0% | ||
| $145.6M-17.6% | $176.6M+14.2% | $154.6M+11.0% | $139.3M-19.2% | $172.3M-15.6% | ||
| $10.5M— | —— | $76.5M+4,681% | $1.6M-96.8% | $49.9M+625% | ||
| 6.7%— | —— | 33.1%+32.0pp | 1.1%-21.3pp | 22.5%+27.3pp | ||
| $11M-25.2% | $14.7M-3.3% | $15.2M+3.4% | $14.7M0.0% | $14.7M-0.7% | ||
| $2.9M+113% | -$22.8M-20.6% | -$18.9M-2.7% | -$18.4M-143% | $42.8M+336% | ||
| $0-100% | $12.2M— | $0— | $0+100% | -$12.2M— | ||
| $13.4M— | —— | $57.6M+443% | -$16.8M-118% | $92.7M+436% | ||
| $6.6M+69.2% | $3.9M-39.1% | $6.4M+233% | -$4.8M-119% | $24.7M+568% | ||
| $6.8M— | —— | $51.2M+527% | -$12M-118% | $68M+317% | ||
| 4.4%— | —— | 22.2%+30.7pp | -8.5%-39.1pp | 30.6%+46.7pp | ||
| $0.07— | —— | $0.91+514% | -$0.22-118% | $1.19+309% | ||
| $0.13— | —— | $0.96+536% | -$0.22-118% | $1.25+319% | ||
| 56.5M-0.4% | 56.7M+0.4% | 56.5M+4.2% | 54.2M-5.4% | 57.3M+8.1% | ||
| 51.9M-3.0% | 53.5M+0.6% | 53.2M-1.8% | 54.2M-0.4% | 54.4M+2.6% | ||
| $16.5M+1.2% | $16.3M0.0% | $16.3M+0.6% | $16.2M-0.6% | $16.3M0.0% | ||
| $0— | —— | —— | $0+100% | -$12.2M— | ||
| $13.9M— | —— | -$3.7M0.0% | -$3.7M-105% | $69.7M— | ||
| $156.1M+5.0% | $148.7M-35.7% | $231.1M+64.0% | $140.9M-36.6% | $222.2M+14.1% | ||
| $10.5M— | —— | $76.5M+4,681% | $1.6M-96.8% | $49.9M+625% | ||
| $34M— | —— | $99.9M+298% | $25.1M-66.7% | $75.3M+356% | ||
| $34M— | —— | $99.9M+298% | $25.1M-66.7% | $75.3M+356% | ||
| 21.8%— | —— | 43.2%+25.4pp | 17.8%-16.1pp | 33.9%+25.4pp | ||
| $10.5M— | —— | $76.5M+4,681% | $1.6M-96.8% | $49.9M+625% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Emergent Biosolutions's revenue?
- Emergent Biosolutions (EBS) generated $676.8M in revenue over the trailing twelve months, down 29.9% year over year.
- Is Emergent Biosolutions profitable?
- Emergent Biosolutions reported $114.0M in net income over the trailing twelve months, a 9.6% net margin.
- What are Emergent Biosolutions's profit margins?
- Gross margin is 54.2% and operating margin is 15.0%, with a 9.6% net margin.
- What is Emergent Biosolutions's earnings per share?
- Emergent Biosolutions's diluted EPS over the trailing twelve months is $1.95.
- Where does Emergent Biosolutions's income statement data come from?
- Every line is extracted from Emergent Biosolutions's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
